


SurgihoneyRO™ and Reactive Oxygen™ hailed as a "British breakthrough that could be of enormous significance" in fight against antimicrobial resistance by leading science writer

By Matoke Holdings Ltd, December 19, 2016



Dr Matthew Dryden, consultant microbiologist and infection specialist MBBS, MD, FRCPath

REACTIVE Oxygen[™] was highlighted in The Times today (Monday December 19) as "a British breakthrough that could be of enormous significance" in the war against antimicrobial resistance (AMR).

Science writer Matt Ridley featured SurgihoneyRO[™] (also known as Surgihoney) in his column on the topic of biomedical innovation, entitled 'Our brilliant biologists are changing the world.'

Lord Ridley, a peer, pointed out how many of the great discoveries and inventions in life sciences have happened in Britain despite it only having one per cent of the world's population.

He lists British "bio-firsts" and "triumphs", including mitochondrial replacement therapy (misleadingly-termed three-parent babies), penicillin, in-vitro fertilisation and DNA fingerprinting. And he asks if this trend can continue.

Lord Ridley wrote: "I think so. In recent weeks, I have been briefed on two British breakthroughs that could be of enormous significance...

"One is a potential solution to the crisis of antimicrobial resistance, which is killing 700,000 people a year worldwide and is the subject of international debate. A start-up called Matoke Holdings has a product called Surgihoney, whose trick is to generate reactive oxygen (the same chemistry as in disinfectants) but slowly, continuously and in the right place,

"Early results with Surgihoney and other delivery mechanisms show that this can be effective against bacteria in circumstances where antibiotics don't work well: recurrent sinusitis, chronic respiratory conditions, cystic fibrosis, chronic wounds and burns, surgical prophylaxis and recurrent urinary infection caused by multi-resistant bugs.

"A doctor friend and expert on antimicrobial resistance, Matthew Dryden, who has tested it, calls it a potential game changer."

Dr Dryden, a consultant microbiologist and director of infection at Hampshire Hospitals NHS Foundation Trust, has pioneered the clinical use of SurgihoneyRO™ & Reactive Oxygen™ technology to both prevent and treat infections, including MRSA, *Pseudomonas aeruginosa and E.coli*.

Matoke Holdings Ltd is collaborating with leading scientists and surgeons at Southampton and Birmingham universities to develop new delivery vehicles and medical applications.

.Notes to editors

Read Matt Ridley's column http://www.thetimes.co.uk/edition/comment/our-brilliant-biologists-are-changing-the-world-t9d0fvv8l

See www.reactiveoxygen.co.uk for all published medical papers.

For more information, interview or case study requests contact: Contact Rachel Masker Rachel.masker@matokeholdings.com